Ultimately, it has been demonstrated that NCT503, Tubeimoside-I, GNA13, Pyrviniumpamoate, DEC1, METTL3, and MMR improve GBM sensitivity to TMZ treatment by controlling MGMT 140-146. Here, MGMT is linked to glioblastoma.